What a New Study Found About MOTS-c and Muscle Mitochondrial Function

What Did This New MOTS-c Study Actually Test?

A research group at the University of Copenhagen — spanning the Section for Cell Biology and Physiology and the August Krogh Section for Human and Molecular Physiology — published a mechanistic study of MOTS-c, the 16-amino-acid mitochondrial-derived peptide, in Free Radical Biology and Medicine.[1] The paper, led by Gudiksen, Hansen, van der Stede and colleagues with Pilegaard as senior author, asks a narrower and more mechanistic question than most MOTS-c coverage: not whether MOTS-c is associated with metabolic health, but which specific signalling proteins its effect on skeletal-muscle mitochondria actually depends on.[1]

This is basic preclinical science, not a clinical trial. No human participant in this study received MOTS-c — a distinction covered in full below.

What Did the Mouse Experiments Show?

To isolate which pathway MOTS-c signals through, the researchers used two separate inducible knockout mouse strains: PGC-1α muscle-specific inducible knockout (iMKO) mice, lacking the transcriptional coactivator that governs mitochondrial biogenesis and oxidative gene expression, and AMPKα1/α2 inducible double-knockout (iMDKO) mice, lacking the cell's central energy-sensing kinase.[1] Female mice from each knockout line, alongside wild-type controls, received MOTS-c at 5.0 mg/kg by intraperitoneal injection, five days a week for four weeks.[1]

In wild-type mice, MOTS-c improved intrinsic mitochondrial bioenergetic performance and efficiency in skeletal muscle — meaning the mitochondria present became better at producing usable energy relative to their size, rather than the muscle simply growing more mitochondria. The study found no corresponding increase in mitochondrial respiratory protein content, pointing to a change in mitochondrial quality rather than mitochondrial quantity (biogenesis).[1] MOTS-c treatment also lowered mitochondrial reactive oxygen species (ROS) emission and reduced ROS-related protein damage, indicating less cellular oxidative stress in treated muscle.[1]

What Happened in the Human Exercise Arm?

Separately from the mouse-dosing experiments, the researchers ran a small human physiology component using skeletal-muscle interstitial microdialysis — a technique that samples the fluid surrounding muscle fibres via a thin probe, rather than drawing whole blood.[1] Eight healthy males aged 18–40, screened by medical examination, 12-lead ECG and blood sampling, had microdialysis probes placed in the vastus lateralis (outer thigh muscle) and gave dialysate samples at rest and during a graded one-legged knee-extensor exercise protocol: three consecutive 20-minute bouts at 10W, 20W and 10W.[1]

No participant in this arm received exogenous MOTS-c. The human component measured each volunteer's own naturally produced MOTS-c during exercise; it did not test, dose, or evaluate an injected or investigational MOTS-c product in people. That distinction matters for anyone reading trial-style claims into this paper — the interventional dosing in this study is confined entirely to the mouse arm.

Why Does the PGC-1α/AMPK Dependency Matter?

PGC-1α is widely described in the muscle-physiology literature as the master transcriptional coactivator for mitochondrial biogenesis and oxidative metabolism, while AMPK is the cell's central sensor of energy status, activated when the ATP:AMP ratio falls. Earlier MOTS-c literature, summarised in our MOTS-c research overview, has already proposed that MOTS-c activates AMPK in skeletal muscle by interfering with the folate cycle and driving accumulation of the AMPK-activating intermediate AICAR. This new paper builds directly on that model by adding PGC-1α as a second, co-required node, and by showing the downstream effect is specifically on mitochondrial bioenergetic efficiency and redox balance rather than mitochondrial volume.[1]

For research design, that distinction is practically useful: a cell or animal model with disrupted PGC-1α or AMPK signalling — whether through genetic knockout, pharmacological inhibition, ageing, or disease state — may not reproduce MOTS-c's bioenergetic effects even at an identical dose, since the pathway the peptide appears to require would itself be compromised.

How Does This Fit With the Rest of Current MOTS-c Research?

This paper sits alongside, but is entirely distinct from, Hudson Biotech's Phase 2a clinical trial of MOTS-c (NCT07505745), which is dosing investigational MOTS-c in adults with prediabetes and overweight or obesity to measure insulin-sensitivity outcomes. That trial tests a clinical efficacy question in a patient population; this Copenhagen paper is upstream basic science, using genetic mouse models and human microdialysis to map the molecular pathway rather than a therapeutic outcome. Neither study's results depend on or inform the other's design.

It also adds mechanistic depth to a growing but still largely observational human MOTS-c literature, which has separately reported that circulating MOTS-c levels differ between lean and obese adults and correlate with markers such as BMI and insulin resistance — associations, not interventions. What this new paper contributes that observational cohort work cannot is a controlled test of causality: dosing MOTS-c directly, in defined genetic backgrounds, to see which pathway is actually necessary for its effect.

What Are the Limitations of This Study?

The knockout-mouse experiments used female mice only, so the findings should not be assumed to generalise to male animals or to other species without further testing. Dosing was intraperitoneal at a fixed 5.0 mg/kg regimen in mice, which does not establish a human-equivalent dose or route, and the human arm was a small (n=8), single-sex, healthy-volunteer, non-interventional microdialysis study — it was not designed or powered to test an efficacy question, and it did not administer MOTS-c to any participant.[1]

As with any single mechanistic paper, replication in independent labs, in male animals, and eventually in a controlled human-dosing design would be needed before this PGC-1α/AMPK dependency could be treated as an established feature of MOTS-c pharmacology rather than a well-supported hypothesis from one research group's model system.

What Should UK Researchers Take From This?

This paper is a useful addition to the mechanistic evidence base for researchers designing MOTS-c studies, particularly anyone selecting cell lines or animal models where PGC-1α or AMPK signalling may be altered. It has no bearing on the regulatory status of research-use peptides in the UK: MOTS-c remains an unlicensed research compound, and nothing here changes the position set out in our guide on whether research peptides are legal in the UK.

Velox Peptides supplies MOTS-c strictly as an HPLC-verified in vitro research reagent, with batch documentation available on request and no dosing guidance of any kind.

MOTS-c is referenced here for research-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions